<DOC>
	<DOCNO>NCT00587691</DOCNO>
	<brief_summary>The purpose study 1 ) study safety tolerability escalate dos myelin peptide reactive T cell MS patient 2 ) study clinical effectiveness T Cell Vaccine ion clinical course MS .</brief_summary>
	<brief_title>Dose-Escalation Study T Cell Vaccine Multiple Sclerosis</brief_title>
	<detailed_description>The principle TCV similar traditional microbial vaccination attenuate infectious agent use stimulate protective immune response . Because pathogentic autoreactive T cell view pathogen T cell-mediated autoimmune disease , use , vaccine prevent treat disease able induce .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Stable MS disease within 30 day prior enrollment EDSS Score 2 8 inclusively Failed respond tolerate least 1 currently approve drug MS. Women pregnant breastfeed plan become pregnant study Has take immunomodulating drug within 60 day prior screen HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tovaxin</keyword>
	<keyword>TCV</keyword>
	<keyword>Autologous</keyword>
</DOC>